Trials / Recruiting
RecruitingNCT07303894
A Study of Isoquercetin in People With Ovarian Cancer
Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Isoquercetin | Cohort B and Cohort C will take isoquercetin |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2026-01-22
- Primary completion
- 2032-01-01
- Completion
- 2032-01-01
- First posted
- 2025-12-26
- Last updated
- 2026-04-16
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07303894. Inclusion in this directory is not an endorsement.